Biosplice is committed to developing safe and effective medical solutions to help patients. Biosplice may, in the future, provide access to its investigational drug products for expanded access, sometimes called “compassionate use,” if and when there is sufficient scientific evidence to support an expectation of net benefit to the specific patient and where such use would not unduly jeopardize the investigational product’s potential to benefit a larger patient population.
Biosplice is not offering expanded access for any investigational drug product at this time.